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Abstract 
Background: Diabetes mellitus has multiple complications including neuropathy and increases cardiovascular 
events. Paeoniflorin (PF), a monoterpene glycoside, plays an essential role in neuroprotection and ischemic heart 
disease. In this study, we aimed to investigate the hypothesis that PF protects mice with diabetes mellitus against 
myocardial ischemic injury, and determine its associated mechanisms.
Results: Myocardial infarction (MI) was generated in the streptozotocin-mediated diabetic mice, which were pre-
treated with either vehicle or PF, respectively. Myocardial infarct size, myocardial enzyme, cardiac function, circulating 
calcitonin gene-related peptide (CGRP) concentration, histological analysis and the expression of associated mole-
cules were determined and compared among different experimental groups. Compared to diabetic hearts pretreated 
with vehicle, hearts pretreated with PF exhibited less tissue damage and better CGRP concentration in serum when 
subjected to myocardial ischemia. Transient receptor potential vanilloid 1(TRPV1) gene knockout attenuated PF-
mediated cardioprotection. Moreover, a specific Ca2+/calmodulin-dependent protein kinase (CaMK) inhibitor, KN-93, 
increased tissue damage and decreased CGRP activity in serum. Meanwhile, pretreated with PF increased the phos-
phorylation of cAMP response element binding protein (CREB).
Conclusions: Taken together, these findings demonstrate that PF protects diabetic mice against MI at least partially 
via the TRPV1/CaMK/CREB/CGRP signaling pathway.
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Background
Diabetes mellitus (DM) has become a global problem 
that threatens human health [1, 2]. DM is characterized 
by increased plasma glucose levels and is often accompa-
nied by several complications including microangiopathy, 
neuropathy and mobilopathy, which lead to high morbid-
ity and mortality [3–5]. High blood glucose also impairs 
nerve fibers such as the sensory nerve fiber, which can 
give rise to painless myocardial infarction and reduce 
synthesis and release of neuropeptide; subsequently 
resulting in increased morbidity related to cardiovascular 
events and morbidity of sudden cardiac death (SCD) [6].
Transient receptor potential vanilloid 1 (TRPV1) is a 
non-selective cation channel that is mainly expressed 
in sensory neurons. Pharmacological studies have 
shown that TRPV1 exerts an important cardiopro-
tective effect [7–9]. Previous studies have indicated 
that TRPV1 and its main neuropeptides calcitonin 
gene-related peptide (CGRP) and substance P sig-
nificantly decreased in diabetic hearts, which was 
related to the poor recovery of cardiac function after 
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myocardial ischemia [10, 11]. CGRP, the major neuro-
peptide released from nerve terminals, has both posi-
tive inotropic and potent vasodilatory effects which 
lead to augment post-ischemic cardiac performance 
[12]. Moreover preconditioning with CGRP protected 
against ischemia/reperfusion (I/R) injury in isolated 
hearts of rats [11].
The activation of TRPV1 by physical and/or chemical 
stimuli induces Ca2+ influx into neurons, leading to the 
activation of Ca2+-mediated signal transduction includ-
ing the activation of Ca2+/calmodulin-dependent pro-
tein kinase (CaMK) [13–15]. CaMK is a multifunctional 
serine/threonine family with four isoforms, including 
Ca2+/calmodulin-dependent protein kinase II (CaMKII). 
A number of studies have reported that CaMK signaling 
is critical for a variety of neuronal functions. One of the 
downstream molecules of CaMKII is the cAMP response 
element binding protein (CREB), which has been identi-
fied as a critical transcription factor in spatial memory 
formation [16–18]. Activation of CREB transcription 
by calcium and cAMP signals increased CRE-mediated 
gene expressions such as structural proteins, signal-
ing enzymes, or growth factors [19–21]. Previous stud-
ies have indicated that the activation of TRPV1 leads 
to an up-regulation of CGRP via CaMK-CREB cascade 
[22–25].
Paeoniflorin (PF) is a monoterpene glycoside, and 
exhibits various pharmacological activities including 
anti-inflammatory [26–29], antioxidant [30, 31] and 
immunoregulatory activities [32–34]. Furthermore, pre-
vious studies have suggested that PF is a potential neu-
roprotective agent. For instance, PF protected rats in 
a cerebral ischemia model [35–37]. PF attenuated the 
nerve injury and regulated the neurotransmitter release 
[29, 38, 39]. More recently, PF has been shown to attenu-
ate acute myocardial infarction in a rat model [40, 41]. 
However, whether PF has any effects on ischemic heart in 
a DM model remains uninvestigated.
In this study, we investigated whether PF could pro-
tect DM mouse heart from MI-induced injury using an 
experimental MI model in DM mice. We found that PF 
protected diabetic hearts from MI-induced injury. We 
also provided evidence that the protective effects of PF 
on MI-induced cardiac injury was mainly via the TRPV1/
CaMK/CREB/CGRP signaling pathway. Our findings 
provide novel insights into the molecular basis underly-
ing PF-induced cardiac protection against ischemia in a 
DM model.
Results and discussion
Body weight and plasma glucose
Eight weeks after STZ injection, body weight and plasma 
glucose were measured to select the appropriate mice, 
and they showed no significant difference among the 
groups before surgery (data not shown).
PF attenuates MI‑induced cardiac injury
As shown in Fig. 1a, infarct size in mice treated with 70 
or 140  mg/kg of PF for 14  days was smaller, compared 
with mice in the WTDM group. Although there was 
no statistical difference between the PF-WTDM-L and 
WTDM groups in terms of infarct size, a high dose of PF 
(140  mg/kg) significantly reduced infarct size compared 
with the WTDM group. During myocardial infarction, 
degradation of membrane integrity leads to the leakage of 
myocardial enzymes into the serum. Thus, the concentra-
tion of certain myocardial enzymes in serum reflects the 
severity of myocardial tissue injury. We measured some 
myocardial enzymes such as CK, CKMB, GOT, α-HBDH 
and LDH; and found that these enzymes were elevated 
in the serum of DM mice in vehicle, PF-WTDM-L and 
PF-WTDM-H groups. As shown in Fig. 1b, a PF dose of 
140  mg/kg significantly decreased the levels of all these 
tested enzymes (Fig.  1b). Next, we measured the con-
centration of CGRP in the serum of mice in each group 
before and after MI surgery at different time points, as 
indicated in Fig. 1c. There was no difference in the activity 
of CGRP at baseline between each group. However, CGRP 
levels remarkably increased in each group subjected to 
ischemia; which peaked at 6 h after MI (P < 0.05). PF sig-
nificantly enhanced the release of CGRP. Furthermore, 
PF significantly improved cardiac function (EF and FS) 
at day 1 and 7 after surgery, compared with the WTDM 
group (Fig. 1d). Next, we probed whether PF could change 
expression of TRPV1 by performing Western Blots on 
protein lysates purified from both the left ventricle and 
dorsal root ganglion (DRG) of mice in the WTDM and 
PF-WTDM-H groups, respectively. As shown in Fig.  1e, 
PF treatment significantly induced TRPV1 expressions 
in both the heart and DRG. Collagen production and 
deposition were evaluated by Massion’s trichrome stain-
ing of histological sections of the hearts. A high dose of 
PF strikingly reduced the interstitial fibrotic area in hearts 
compared with the WTDM group (Fig. 1f ). These results 
indicate that pretreatment with PF significantly elevates 
the concentration of CGRP in plasma, which is a protec-
tive factor for diabetic hearts against MI-induced injury.
TRPV1 gene knockout partially suppresses PF‑mediated 
cardioprotection against MI
Next, we used TRPV1 gene knockout mice to explore 
whether TRPV1 was involved in PF-mediated protec-
tion against MI. TRPV1 gene knockout had no sig-
nificant effect on the severity of myocardial injury, 
compared with the WTDM group (Fig.  2a). PF signifi-
cantly decreased infarct size and myocardial enzyme 
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levels in mice in both WTDM and TRPV1−/−DM 
groups (P  <  0.05, Fig.  2a, b). However, knockout of 
TRPV1 reduced the effect of PF on both infarct size and 
serum myocardial concentration (P < 0.05, Fig. 2a, b). In 
addition, TRPV1−/− hearts (PF-TRPV1−/−DM) released 
less CGRP, compared with hearts in the PF-WTDM-H 
group (Fig. 2c). As shown in Fig. 2d, PF improved car-
diac function in both TRPV1−/−DM and WTDM mice. 
However, the cardioprotective effects of PF were sig-
nificantly better in WTDM hearts than in TRPV1−/− 
hearts. PF reduced the interstitial fibrotic area in both 
WTDM and TRPV1−/−DM hearts, but the area in 
PF-WTDM-H was less than PF-TRPV1−/−DM group 
(Fig. 2e). These findings suggest that PF-mediated myo-
cardial protection is achieved at least in part via TRPV1.
Blockade of CaMKII attenuates the protective effects of PF 
on MI‑induced heart injury in DM mice
We next measured CaMKII levels in the hearts of the 
above mentioned groups of mice, and did not observe 
any significant change between the two groups (Fig. 3a), 
its activity as a kinase might be involved in PF-mediated 
Fig. 1 Paeoniflorin (PF) protects the heart against MI-induced injury in DM mice. a PF decreased myocardial infarct size. The black arrow indicates 
the infarction site. b PF decreased the release of myocardial enzymes in serum, including CK, CKMB, GOT, a-HBDH, and LDH. c the activity of CGRP 
in serum measured at different time points before and after MI. d Heart function was analyzed by measuring fractional shortening {FS = [LV end-
diastolic diameter (LVEDD) − LVend-systolic diameter (LVESD)] × 100/LVEDD} and LV ejection fraction [LVEF = (LVEDD2 − LVESD2)/LVEDD2]. d Repre-
sentative immunoblots of TRPV1 expression are shown. GAPDH was used as control. The lower panel shows the statistical analysis of the upper panel; 
*P < 0.05. f Representative images of hematoxylin and eosin (1–4) and Masson’s trichrome staining (5–8); (1 and 5) normal group (2 and 6) WTDM 
group (3 and 7) PF-WTDM-L group (4 and 8) PF-WTDM-H group. WTDM group: WTDM mice were pretreated with saline, PF-WTDM-L group: WTDM 
mice were pretreated with PF (70 mg/kg) before surgery, and PF-WTDM-H group: WTDM mice were pretreated with PF (140 mg/kg) before surgery 
(n = 6 per group; *P < 0.01, PF-WTDM-H vs. WTDM)
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myocardial protection. KN-93, a selective CaMKII 
inhibitor, was used to test whether CaMKII activity is 
involved in PF-mediated myocardial protection. As 
shown in Fig.  3b and c, KN-93 significantly increased 
the concentration levels of circulating myocardial 
enzymes and infarct size in DM hearts, compared with 
vehicle-treated hearts. In addition, the release of CGRP 
significantly decreased when DM mice were pretreated 
with KN-93 (Fig.  3d). As shown in Fig.  3e, KN-93 
attenuated the recovery of cardiac function, compared 
with the PF-WTDM-H group. Meanwhile, KN-93 also 
increased the interstitial fibrosis area compared with 
PF-WTDM-H group (Fig.  3f ). These results indicate 
that CaMKII plays an important role in PF-mediated 
cardioprotection. Furthermore, TRPV1 gene knock-
out did not synergize with KN-93 to increase infarct 
size and release myocardial enzymes (data not shown) 
and the concentration of CGRP in serum were similar 
(Fig.  3g). Thus, we conclude that CaMKII is a down-
stream of TRPV1.
Fig. 2 TRPV1 gene knockout partially abrogates paeoniflorin (PF)-mediated cardioprotection against MI. a TRPV1 knockout attenuated the 
decrease in myocardial infarct size by PF treatment, the black arrow indicates the infarction site. b TRPV1 knockout repressed the beneficial effects 
of PF on the release of myocardial enzymes in serum; c the activity of CGRP in serum measured at different time points before and after myo-
cardial ischemia. d Heart function was assessed by fractional shortening {FS = [LV end-diastolic diameter (LVEDD) − LVend-systolic diameter 
(LVESD)] × 100/LVEDD} and ejection fraction [LVEF = (LVEDD2 − LVESD2)/LVEDD2]. e Representative images of hematoxylin and eosin (H&E, 1–4) 
and Masson’s trichrome staining (5–8); (1 and 5) WTDM group (2 and 6) PF-WTDM group, (3 and 7) TRPV1−/−DM group, (4 and 8) PF-TRPV1−/−DM. 
PF-WTDM group: WTDM mice were pretreated with PF (140 mg/kg) before surgery, and TRPV1−/−DM group: TRPV1 gene knockout mice with 
diabetes mellitus; PF-TRPV1−/−DM, TRPV1 gene knockout DM mice were pretreated with PF (140 mg/kg) before surgery; n = 6 per group; *P < 0.01, 
PF-TRPV1−/−WTDM vs. PF-WTDM-H; #P < 0.05, PF-TRPV1−/−DM vs. TRPV1−/−DM. (Mean ± SEM)
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PF increases the phosphorylation of CREB (pCREB)
Previous studies have shown that pCREB regulated 
CGRP levels [42]. Thus, we determined whether PF 
could increase the release of CGRP via increased pCREB. 
pCREB levels in PF-DM hearts were significantly higher 
than in control mice. Both TRPV1 gene knockout and 
KN-93 suppressed the levels of pCREB. Taken together 
(Fig.  4), these findings indicate that PF potentiates 
Fig. 3 KN-93 attenuates the beneficial effects of paeoniflorin (PF) in DM mice. a PF treatment did not significantly alter CaMKII expression levels in 
hearts of mouse. The lower panel shows the statistical analysis results of the upper panel; GAPDH, n = 6/group. b KN-93 attenuated the PF-induced 
decrease in myocardial infarct size, the black arrow indicates the infarction site. c KN-93 inhibited the PF-repressed release of myocardial enzyme in 
serum. d KN-93 decreased the PF-induced increase in CGRP levels in serum at different time points after myocardial ischemia. e Heart function was 
assessed by fractional shortening and ejection fraction. f Representative images of hematoxylin and eosin (H&E, 1–3) and Masson’s trichrome stain-
ing (4–6); (1 and 4) WTDM group, (2 and 5) PF-WTDM-H group, (3 and 6) PF-WTDM-KN-93. g CGRP levels in serum pretreated with PF in mice of the 
two groups as indicated. PF-WTDM-KN-93 group, PF-WTDM mice were pretreated with KN-93 at 10 min prior to coronary artery ligation; n = 6 per 
group. (*P < 0.05, PF-WTDM-H vs. WTDM; #P < 0.05, PF-WTDM-KN-93 vs. PF-WTDM-H)
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pCREB; which can be blocked by either TRPV1 gene 
knockout or the CaMKII inhibitor.
Discussion
The main findings of the present study are as fol-
lows: First, PF indeed protected the DM heart against 
MI-induced injury, as evidenced by reduced myocar-
dial infarct size, decreased myocardial enzyme release, 
improved cardiac function recovery, increased the 
expression of TRPV1 and release of CGRP in serum in 
PF-pretreated diabetic mice; second, TRPV1 gene knock-
out partially suppressed PF-mediated cardioprotection; 
third, KN-93, a specific inhibitor for CaMKII, attenu-
ated the protective role of PF in wild type DM mice, and 
did not change the CGRP concentration in TRPV1 gene 
knockout mice, which is consistent with the notion that 
CaMKII is a downstream of TRPV1; fourth, PF-mediated 
cardioprotection was related to the phosphorylation of 
CREB.
Coronary artery disease remains the leading cause 
of death in patients with DM. Diabetic mice dis-
played exacerbated injury following myocardial 
ischemia–reperfusion and are resistant to most thera-
peutic interventions [43, 44]. With the increasing num-
ber of diabetic patients and its complex complications, 
it is important to explore the application values of PF on 
diabetic mice with myocardial ischemia injury.
Myocardial ischemia is the leading cause of death 
worldwide, and a wealth of evidence points to the mul-
tiple mechanisms underlying the MI-induced injury 
including inflammatory and oxidative stress. Our previ-
ous researches have provided the evidence for a role of 
the neuropeptide in the progression of MI [7, 8]. Dia-
betic neuropathy, including central nervous and periph-
eral nerve, is one of the most frequent complications 
of DM and results in a poor prognosis and increased 
mortality, and the impaired afferent fibers that run in 
the cardiac sympathetic nerves play the essential role in 
silent myocardial ischemia in DM patients. The activa-
tion of TRPV1, which is expressed in sensory nerve fib-
ers, could mediate the transmission of pain and activate 
the synthesis and release of cardiacprotective neuro-
peptides [12, 45]. Thus, TRPV1 was speculated to play 
a multiple part in DM mice subjected to myocardial 
ischemia. Our previous studies revealed that neuropathy 
was obvious after 8 weeks in the mice with STZ-induced 
DM, in which both TRPV1 and CGRP were impaired in 
DM heart and subsequently increased the MI-induced 
injury [10]. In present study, we showed that PF signifi-
cantly attenuated the MI-induced injury. Meanwhile, 
we also found that PF reversed the impaired TRPV1 in 
DM mice, which is consistent with the neuroprotective 
function of PF. This study is the first to investigate the 
protective effects of PF on myocardial ischemia from the 
view of improving diabetes-induced nerve injury. Thus, 
our study provides evidence that PF may potentially have 
beneficial effects on DM patients with neuropathy or 
coronary heart disease.
TRPV1 is a Ca2+-permeable channel protein, and the 
activation of the TRPV1 channel increases the concentra-
tion of intracellular Ca2+ and, in turn, activates CaMKII. 
The activation of CaMKII subsequently promotes the 
phosphorylation of CREB, which has an essential role in 
CaMK-mediated the up-regulation of CGRP levels [27]. 
In our study, we explored the role of TRPV1 in the PF’s 
cardioprotection in the TRPV1 gene knockout mice. We 
found that the PF pretreated TRPV1−/−DM mice showed 
worse heart injury than in WTDM mice, suggesting that 
TRPV1 gene knockout suppress PF-mediated cardiopro-
tecion. In addition, the blockade of CaMKII by a specific 
inhibitor, KN-93, attenuated the effects of PF in WTDM 
mice, and this inhibition in TRPV1−/−DM mice did not 
significantly change the concentration of CGRP in serum, 
further demonstrating that CaMKII was a downstream of 
TRPV1 signaling. Another important finding is that PF 
Fig. 4 Paeoniflorin (PF) increases the phosphorylation of CREB 
(pCREB). The level of pCREB was significantly higher in the PF-WTDM 
group than in the other groups. a A representative image of the levels 
of pCREB, CREB and GAPDH. b Quantification by the ratio of pCREB to 
GAPDH (n = 6/group). c Quantification by the ratio of pCREB to CREB. 
*P < 0.05, PF-WTDM-H vs. WTDM, TRPV1−/−DM, PF-TRPV1−/−DM, 
PF-WTDM-KN-93 and PF-TRPV1−/−DM-KN-93
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promoted the phosphorylation of CREB, which was sup-
pressed by TRPV1 gene knockout and CaMKII inhibitor. 
These findings support the views of the TRPV1-CaMKII-
CREB signaling cascade [46]. Our study has shed light 
into the mechanisms underpinning PF-induced cardiac 
protection in DM mice subjected to myocardial ischemia, 
and provides rationales to support further studies in our 
traditional Chinese medicine.
Several limitations in our study need to be pointed 
out. First, we only explored PF-mediated TRPV1 
changes in the heart and DRG, and whether PF can offer 
neuroprotection needs further studies. Second, our 
study revealed that PF protected TRPV1−/−DM hearts, 
indicative of the involvement of other pathway(s) in 
PF-mediated cardioprotection in DM heart. Third, the 
exact mechanisms by which PF improved cardiac func-
tion remains unclear, and this may be achieved via 
either the direct interaction of PF with TRPV1, or the 
anti-inflammatory and anti-oxidative mechanisms of PF, 
or both. Fourth, although we provide evidence showing 
that PF may represent a potential new therapeutics for 
DM patients with coronary heart disease or neuropa-
thy, clinical trial needs to be carried out for its clinical 
application.
Conclusions
In conclusion, our study demonstrates that PF provides 
cardioprotection against MI-induced injury at least in 
part via increasing the activity of CGRP in serum in DM 
mice. We have also provided evidence that the TRPV1/





Antibodies against TRPV1 and GAPDH were obtained 
from Cell Signaling Technology (Boston. USA); PF was 
purchased from Zeheng corporation (Hangzhou, China); 
anti-CaMKII was obtained from Abcam (UK); anti-CREB 
and anti-pCREB were obtained from CST (USA); Evans 
blue was purchased from Sigma–Aldrich (Saint Louis, 
MO, USA); and 2,3,5-triphenyltetrazolium chloride 
(TTC) was purchased from Biosharp (Anhui, China). 
KN-93 was purchased from Selleck (USA).
Animals
TRPV1 gene knockout mouse was obtained from 
the Jackson Laboratory (Bar Harbor, ME, USA), and 
TRPV1−/− genotype was confirmed by PCR based on the 
protocol provided by the Jackson Laboratory. Matching 
control WT strain C57BL/6J mice (Shanghai Laboratory 
Animal Center of the Chinese Academy of Sciences), 
weighing 20–22  g, were used in this study. Mice were 
housed under a standard SPF environment with a 12-h 
dark-light cycle, and free access to water and food were 
provided, as previously reported [47]. All animal experi-
ments were conducted in accordance with the Guidelines 
for the Care and Use of Laboratory Animals, and were 
approved by the Animal Ethics Review Committee of 
Zhejiang University.
Experimental protocols
Male C57BL/6J and age-matched TRPV1 gene knock-
out mice were subjected to intraperitoneal injection with 
150  mg/kg of streptozotocin (STZ) in a fasting state. A 
OneTouch® SureStep™ Blood Glucose Monitoring Sys-
tem (LifeScan, USA) was used to measure plasma glu-
cose levels at 3 days and 8 weeks post-STZ injection. A 
blood glucose concentration >16.7  mmol/l were up to 
the criteria at 3 days and 8 weeks for experimental DM 
mice [48]. Detailed experimental protocols are shown 
in Fig.  5. Basically, mice were randomly divided into 
seven groups: WTDM, PF-WTDM-L, PF-WTDM-H, 
TRPV1−/−DM, PF-TRPV1−/−DM,PF-WTDM-KN-93, 
and PF-TRPV1−/−DM-KN-93.
After DM mice were established based on the plasma 
and urine glucose levels mentioned above, they were 
given 70 or 140  mg/kg/day of PF for 14  days by the 
intragastric route; except the control group, which were 
treated with saline as previously described [49]. After 
drug treatment, an acute myocardial infarction animal 
model was induced by the permanent ligation of the 
left coronary artery. First, mice were anesthetized with 
urethane (1.0  g/kg, intraperitoneally). After left thora-
cotomy, the heart was exteriorized, and the left coro-
nary artery was ligated proximately 2 mm from its origin 
between the pulmonary artery and left atrium with a 8–0 
Prolene suture. Then, mice were housed in conventional 
cages with free access to water and rodent chow.
After more than 14  days of PF treatment in mice, 
repeated boluses of KN-93(300 μg/kg), a selective CaM-
KII inhibitor (Selleck, USA), was administered directly 
into the left ventricle, 10  min before the anterior 
descending branch was blocked.
Measurement of myocardial infarct size
Twenty-four hours after coronary artery ligation, the 
chest was opened, and the heart was perfused with (1 %) 
Evans blue solution (2  ml), into the aorta and coronary 
arteries. The heart was then isolated when its beating was 
slow. After removing the right ventricle and atria, the left 
ventricle was sliced into 1.5-mm-thick cross-sections 
below the ligature. These segments were weighted, and 
incubated with 1 % TTC for 20 min at 37 °C in the dark. 
The non-ischemic area (Evans blue-stained) and ischemic 
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area (TTC-unstained) were analyzed by the ImageJ 
(National Institutes of Health) [50]. Photographs of the 
infarct areas in the total left ventricular area were quanti-
fied as infarct area/left ventricle (INF/LV) using ImageJ 
[8].
Determination for myocardial enzyme in serum
Eyeballs were extracted and blood was collected into a 
test tube. The collected blood was centrifuged at 3000 r/
min for 15 min at 4 °C, and the serum obtained was stored 
at −20 °C. Serum concentrations of myocardial enzymes 
including glutamic-oxaloacetic transaminase (GOT), 
creatine kinase (CK), creatine kinase-MB (CK-MB), lac-
tate dehydrogenase (LDH), and α-hydroxybutyric dehy-
drogenase (α-HBDH) were measured using commercial 
kits (Nanjing Jiancheng Biotechnology Institute, Nanjin, 
China), according to manufacturer’s instructions.
Western blot
Cardiac tissues were lysed in RIPA lysis buffer, proteins 
were extracted, and protein concentrations were meas-
ured using the bicinchoninic acid method. Western blot 
was preformed as previously described [11]. The blot was 
probed with the primary antibody of interest as indicated 
in the Figures, where applicable; and coloration was visu-
alized by the enhanced chemiluminescence kit (Thermo 
Scientific, Rockford, IL, USA). Specific protein bands 
were quantified and normalized to GAPDH.
Radioimmunoassay
Plasma was obtained at 0, 1, 6, 12, 24 and 48  h after sur-
gery was performed on mice. The plasma was prepared as 
described before. CGRP concentration in plasma was meas-
ured with a commercially available rabbit anti-rat CGRP 
radioimmunoassay kit (Phoenix Pharmaceuticals) [51].
Echocardiography
Echocardiography was performed at day 1 and 7 after 
surgery, as previously detailed [52–54]. Mice were anes-
thetized and placed on a warm pad to maintain body 
temperature. Hair was removed from the upper abdomi-
nal and thoracic areas with depilatory cream [55, 56]. 
Two-dimensional echocardiography was performed 
using a high-resolution imaging system with a imaging 
transducer (GE Vingmed Ultrasound). Images were ana-
lyzed offline by a researcher blinded to the murine geno-
types. Ejection fraction (EF) and fractional shortening 
(FS) were calculated from the M-mode parasternal short 
axis view [57, 58].
Histological evaluation
Histopathological changes and collagen distribution 
were estimated by haematoxylin and eosin (H&E) and 
Massion’s trichrome staining. The ventricles were fixed 
in 4  % paraformaldehyde, then embedded with paraffin 
and cut cross-sectionally into 5-µm thick sections. Tis-
sue sections were deparaffinized and stained with H&E 
Fig. 5 Detailed experimental protocols used in the present study. The animals were divided into seven groups: (1) WTDM group: diabetes mellitus 
(DM) in wild type mice; (2) PF-WTDM-L group: WTDM treated with 70 mg/kg of paeoniflorin; (3) PF-WTDM-H WTDM treated with 140 mg/kg of PF; 
(4) PF-WTDM-KN-93 group: KN-93 was used to treat DM mice; (5) TRPV1−/− DM: TRPV1−/− mice was used for the DM model; (6) PF-TRPV1−/− DM: 
TRPV1−/− DM treated with 140 mg/kg of PF; (7) PF-TRPV1−/− DM-KN-93 group, KN-93 was used to treat TRPV1−/− DM mice (n = 6/group)
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or Massion’s trichrome reagent. The particular procedure 
was described before [59]. The analysis of the picture was 
using ImageJ.
Statistical analysis
Data are expressed as mean  ±  SEM. Statistical signifi-
cance was determined by student’s t test. A P < 0.05 was 
considered statistically significant.
Abbreviations
DM: diabetes mellitus; PF: paeoniflorin; MI: myocardial infarction; TRPV1: 
transient receptor potential vanilloid 1; CGRP: calcitonin gene-related peptide; 
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element binding protein; DRG: dorsal root ganglion.
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